Liquid Biopsy: Current Status and New Challenges (2nd Edition)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: 10 October 2024 | Viewed by 1123
Special Issue Editor
Interests: liquid biopsy; circulating tumor cells (CTCs); platelets educated tumor (PETs); extracellular vesicles (EVs); circulating tumor nucleic acids (ctNA); cancer interception (CI)
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is the second edition of a previous Special Issue, “Liquid Biopsy: Current Status and New Challenges” (https://www.mdpi.com/journal/cancers/special_issues/Liquid_Biopsy_Current_Status_New_Challenges).
It is my pleasure to invite you to participate in the development of this Special Issue, which addresses the principal advances and challenges currently facing liquid biopsy.
Liquid biopsy (LB) has been identified as a critical strategic approach in precision medicine (PM). Its use allows us to monitor the patient's evolution in real-time. The most crucial role of LBs is their use as prognostic and predictive markers in different types of tumors, which makes it possible to understand how the disease can evolve and to identify the best treatment according to the presence and characteristics of these LB markers. LBs have been accepted as prognostic and predictive markers in numerous solid tumors, especially in metastatic cancer. Therefore, their use in clinical routine has promoted the need to improve the methodologies for analyzing these markers. Although LBs have as a principal attraction minimal invasiveness and time resolution, most LBs show a common characteristic, “minimal biological amounts” to work, whether we are talking about CTCs, ctDNA, or tumor educated platelets, which makes their use difficult. New methodologies applied to analyze LBs have emerged to address these limitations, including the novel methods of massive sequencing (NGS) or digital PCR. Both allow us to obtain accurate results using minimal samples. This technology accompanies the advances in the clinical implementation of LBs. More importantly, these advances promote the use of the LBs in other fields beyond metastatic cancer. detection of minimal residual disease to predict the risk of relapse in solid tumors is one of the main challenges of using LB. It is also interesting that LBs are now used as diagnostic markers in non-tumoral diseases associated with cancer risk (e.g., colon polyps or lung emphysema) and in cancer interception (the obtention of biological information through a non-invasive biopsy to understand an individual’s real risk of developing cancer).
This Special Issue aims to address the main advances and challenges pertaining to the use of liquid biopsy.
Dr. María Jose Serrano
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- liquid biopsy
- cancer interception
- molecular analyses
- minimal residual disease
- epigenomic
- transcriptomic
